Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase NA 3Phase 1 3Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 23Carboplatin 23pembrolizumab 21Paclitaxel 20Gemcitabine 19Specimen Handling 16Drug Therapy 15Dexamethasone 15Radiotherapy 14Nivolumab 14Doxorubicin 14Bevacizumab 14atezolizumab 13Oxaliplatin 13Cyclophosphamide 13Radiation 11Pemetrexed 11Cytarabine 11venetoclax 10Vincristine 10Prednisone 10Docetaxel 10Capecitabine 10Trastuzumab 9Temozolomide 8Rituximab 8Platinum 8Ipilimumab 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Hematopoietic Stem Cell Transplantation × 1 year × Clear all
NCT04708054 2026-02-19

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

M.D. Anderson Cancer Center

Phase 2/3 Recruiting
324 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡